Trial Profile
Single arm, open label, signal seeking, phase IIa trial of the activity of Olaparib in combination with Durvalumab in patients with tumours with homologous recombination repair defects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Olaparib (Primary)
- Indications Cholangiocarcinoma; Endometrial cancer; Gallbladder cancer; Neuroendocrine tumours; Solid tumours
- Focus Therapeutic Use
- Acronyms MoST Addendum 3
- 26 Jun 2023 Results of post hoc analysis published in the British Journal of Cancer
- 07 Feb 2022 Full patient enrolment was completed on 13 Feb 2019
- 07 Feb 2022 Status changed from active, no longer recruiting to completed.